Key facts
- This page summarizes Mark Neumann's Form 4 filing for Intra-Cellular Therapies, Inc. (ITCI).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 09 Aug 2023, 18:05.
Mark Neumann - 07 Aug 2023 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)
- Reporting relationship
- EVP, Chief Commercial Officer
- Issuer ticker
- ITCI
- Reported as of
- 07 Aug 2023
- Net transaction value
- -$2,223,060
- SEC form
- 4
- Accepted by SEC
- 09 Aug 2023, 18:05:36 UTC
- Prior SEC filing
- 30 Mar 2023
- Next SEC filing
- 08 Nov 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lawrence J. Hineline, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mark Neumann filed Form 4 for Intra-Cellular Therapies, Inc. (ITCI) on 09 Aug 2023.
Change
- Previous filing in this sequence was filed on 30 Mar 2023.
- Current net transaction value: -$2,223,060.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ITCI
transaction
Common Stock
Options Exercise
- Transaction value
- $1,028,027
- Shares
- +55,300
- Change %
- +122%
- Price
- $18.59
- Shares after
- 100,639
- Date
- 07 Aug 2023
- Ownership
- Direct
ITCI
transaction
Common Stock
Sale
- Transaction value
- $3,251,087
- Shares
- -55,300
- Change %
- -55%
- Price
- $58.79
- Shares after
- 45,339
- Date
- 07 Aug 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ITCI
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -55,300
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 07 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 55,300
- Exercise price
- $18.59
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.3319 to $59.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Footnote F2
All shares underlying this option have vested.